Cost of lifetime immunosuppression coverage for kidney transplant recipients. by Page, Timothy F & Woodward, Robert
University of New Hampshire
University of New Hampshire Scholars' Repository
Health Management and Policy Scholarship Health Management and Policy
11-2008





University of New Hampshire - Main Campus
Follow this and additional works at: https://scholars.unh.edu/hmp_facpub
Part of the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by the Health Management and Policy at University of New Hampshire Scholars' Repository. It
has been accepted for inclusion in Health Management and Policy Scholarship by an authorized administrator of University of New Hampshire
Scholars' Repository. For more information, please contact nicole.hentz@unh.edu.
Recommended Citation
Page, T.F., Woodward, R.S. Cost of lifetime immunosuppression coverage for kidney transplant recipients. (2008) Health Care









Timothy F. Page, Ph.D. and Robert S. Woodward, Ph.D. 
On January 1, 2000, Medicare extended 
the coverage of immunosuppression medi­
cations from 3 years to life for elderly and 
disabled kidney transplant recipients. This 
research estimates the impact of extending 
this lifetime coverage to all kidney transplant 
recipients on Medicare’s cash flows. The study 
finds that extending coverage to all kidney 
transplant recipients would have increased 
Medicare’s net cash outflows if the coverage 
were extended for patients of all income lev­
els. There is evidence that extending coverage 
to only patients in the lowest income quartile 
could have resulted in a net cost savings 
to Medicare. 
intrODUCtiOn 
While Medicare in the U.S. only added 
a prescription medication option to its 
benefit package in 2006, it has provided at 
least 1 year coverage of immunosuppres­
sion medications for transplant receipients 
since 1978. Between 1993 and 1995, Medi­
care increased the duration of immuno­
suppression medication coverage from 1 
to 3 years post transplant for all transplant 
recipients. On January 1, 2000, Medicare 
effectively provided lifetime immunosup­
pression medication coverage to trans­
plant receipients over age 65 or disabled, 
but the immunosuppression coverage for 
non-disabled transplant (ineligible) recipi­
ents under age 65 remained at only 3 years
following transplantation.1 
This research estimates the changes in 
Medicare’s net cash flow that would have 
occurred in the years following 2000 if 
Medicare had extended its lifetime cover­
age of maintenance immunosuppression 
medications to all kidney transplant recipi­
ents. Providing lifetime coverage may cre­
ate a cash outflow increase determined 
by the cost of the medications and the 
numbers of transplant recipients whose 
coverage would not have been cancelled. 
Lifetime coverage, however, may reduce 
cash outflows because fewer patients would 
have lost their transplanted kidneys and 
therefore not have incurred the expenses 
of returning to the dialysis. The net impact 
of these competing effects is unclear. 
We found that if Medicare had extended 
lifetime coverage of immunosuppression 
medications to all transplant recipients as 
of January 1, 2000, Medicare’s cash out­
flows would have increased significantly. 
Although there would have been sav­
ings associated with avoiding graft failure 
through increased drug coverage, these 
incremental benefits would have been out­
weighed by the incremental costs of cover­
ing all transplant recipients, most of whom 
would have experienced no improvement 
in graft survival outcomes. 
PreviOUS reSearCH 
Other researchers have attempted to esti­
mate the costs associated with graft failure 
1 Benefits Improvement and Protection Act (2000), Public Law 
106-554. 
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(Yen et al., 2004) and address the question
of whether the improvements in graft sur­
vival that would occur with lifetime drug 
coverage would result in a net savings or 
a net cost to Medicare (Gustafsson et al., 
2005). Yen et al. (2004) used a Markov 
model to determine the cost effectiveness 
of lifetime immunosuppression coverage.
They estimated the costs of graft failure 
to be $137,9302 per patient during the first 
year after failure. Then they combined this
estimate with estimates of quality adjusted
life year improvements and predicted a net 
societal savings of $136 million annually. 
While they included benefits in their anal­
ysis other than potential cost savings, the
strongest case to be made for extending
lifetime coverage to all transplant recipi­
ents would be to show a net cost savings 
to Medicare. For this reason, we exam­
ined this issue from only the perspective 
of Medicare’s cash flows. 
Gustafsson and colleagues (2005) ad­
dressed the question that we attempted 
to answer in this study, that is, whether 
lifetime coverage of immunosuppres­
sion medication would result in a net sav­
ings or a net cost to Medicare. They used 
estimates from the U.S. Congressional 
Budget Office (1999) to conduct a simu­
lation-type analysis of the problem. The 
study focused on the 10-year period fol­
lowing the introduction of the hypothetical
policy. This required projecting forward 
the number of transplants that will occur 
in each year. Assuming an annual cost of 
immunosuppression drugs of $11,781.56 
and an annual post graft failure cost of 
$67,7003 per patient, they estimated that
a coverage extension would generate a 
net cost of $100 million for patients trans­
planted between 2000 and 2004. Also, they 
estimated that for the coverage exten­
sion to be revenue neutral, between 2006 
and 2015, the extended coverage would 
need to improve graft survival rates by 
2.45  percent. 
In this study, we used actual retrospec­
tive data to provide estimates of what 
would have happened if the coverage ex­ 
tension that was implemented on January 
1, 2000, had been extended to all transplant 
recipients. Would it have resulted in a 
net savings or a net cost to Medicare? An 
advantage of our approach is that we have 
actual data on the numbers of transplanted 
individuals, the graft survival rates, and 
the costs associated with graft failure dur­
ing the time period considered. Thus, we 
do not rely on forecasts that may or may 
not accurately describe the problem. 
MetHODS 
Study Sample 
We used data from the USRDS for the 
years 1995 to 2003. Our sample included all 
first, cadaveric, single organ kidney trans­
plant recipients transplanted between 1995 
and 2002 with at least $50 in physician/ 
supplier claims and $5,000 institutional 
claims during the first post transplant year. 
These claims figures were used to identify 
patients for whom Medicare was the pri­
mary payer. If this method of identifying 
Medicare patients were to exclude valid 
cases, this would bias our estimates of 
pre- and post-graft failure treatment costs 
upward. However, because we identify 
the cost savings associated with avoiding 
a graft failure as the difference between 
pre- and post-graft failure costs, this bias 
is likely to be eliminated by taking the pre- 
and post-failure difference.4  Of the trans­
plants performed between 1995 and 2002 
4  We also conduct a sensitivity analysis to determine the extent to 
which the analysis is affected by our parameter assumptions. 
2  This number includes not only the costs to Medicare, but also 
costs to the patient, such as reduced health status. 
3  This estimate is consistent with the 2006 estimate published by 
the United States Renal Data System (USRDS), and the estimate 
found in this study. 
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for which Medicare was the primary payer, 
we were able to match Zip Code median 
incomes to 97.4 percent of the patients. The 
resulting sample contained 49,091 trans­
plants. Of these, 38,861 were identified as 
first, single organ, cadaveric transplants. 
Throughout this analysis, we divided 
our sample into quartiles by Zip Code 
median income obtained from the U.S. 
Census Bureau (2000). While the USRDS 
database does not have information on 
individual incomes, many studies used 
Zip Code median incomes as a proxy for 
individual incomes (Woodward et al., 
2001; 2008). Throughout the analysis, we 
refer to our cohorts by income quartile. 
Quartile 4 represents the highest Zip 
Code median income quartile (defined as 
a median income greater than $47,787), 
quartile 3 represents the second highest 
Zip Code median income quartile (defined 
as a median income between $37,407 and 
$47,787), quartile 2 represents the third 
highest Zip Code median income quartile 
(defined as a median income between 
$30,335 and 37,407), and quartile 1 repre­
sents the lowest Zip Code median income 
quartile (defined as a median income 
less than $30,335). We use the term high 
income to refer to individuals in quartile 4, 
while low income refers to individuals in 
quartiles 1, 2, or 3. 
Although Zip Code median incomes are 
only a proxy for actual incomes, this is the 
best income measure that can be gener­
ated with USRDS data. Further, even if 
actual incomes were available, using them 
might introduce bias into the analysis of 
the relationship between income and graft 
survival. For example, individuals who 
are healthier may be more likely to work. 
This would lead to a correlation between 
income and health status that is not related 
to access to medications. While Zip Code 
incomes are not a perfect proxy for actual 
incomes, as long as any potential misclassi­
fication is random throughout our sample, 
the adoption will not bias our results. 
estimation of graft Failure Costs 
The difference in daily costs between 
patients with functioning grafts and pa­
tients who return to dialysis is central to
the analysis. Using the date of graft failure 
as the reference point (and graphical ori­
gin), we calculated average accumulated
Medicare payment (AAMP) cost curves
for each of the four income quartile. The 
AAMPs for each of the four groups were 
calculated before and after the first day 
post failure. For each day t following the 
failure, the average accumulated payments 
equaled the average accumulated pay­
ments of the previous day plus the average 
incremental payments on day t. The aver­
age incremental payments on day t were 
calculated as the total Medicare payments 
made on day t (MPt) divided by the num­
ber of individuals remaining uncensored
on day t (nt): 
AAMPt =AAMPt-1 + (MPt/ nt) (1) 
where t runs from -730 (2 years before 
graft failure) to 1,825 (5 years after graft 
failure). 
In our analysis of cost saving, we use the 
AAMPt estimates specific to each cohort. 
To determine the additional daily costs 
associated with graft failure, we calculated 
the slope of the cost curves for income 
quartiles 1, 2, and 3 (these are the cohorts 
that would have experienced improved 
graft survival rates from lifetime cover­
age) before and after graft failure. The 
difference in the slopes gave an estimate 
of the daily cost differential between pa­
tients with functioning grafts and patients 
who return to dialysis after graft failure
(Table 1). Additional daily costs were $114, 
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Table 1 
Pre- and Post-Graft Failure Cost Differentials by Income Quartile
­
­ ­ ­  



















Quartile­1­ $162­ $48­ $114­ $21,373­ $7,564 
Quartile­2­ ­122­ ­50­ ­­72­ ­11,767­ ­9,760 





$72, and $98 for income quartiles 1, 2, and 
3, respectively.5  In addition to the extra 
daily costs associated with graft failure, 
payments increased by $21,373, $11,767, 
and $24,722 during the year before graft 
failure for the bottom three quartiles, 
respectively. Because some patients re­ 
main hospitalized immediately following 
graft failure, payments associated with 
graft failure increased by $7,564, $9,760, 
and $9,578 for patients in quartiles 1, 2, 
and 3, respectively, in the days following 
the graft failure.6  If the graft failures were 
to be avoided, Medicare would avoid the 
daily cost differential and these extra costs 
associated with trying to save the graft. 
estimation of graft Survival Benefits 
To determine the differences in graft 
survival rates between high and low 
income ineligibles, we constructed Kaplan-
Meier survival curves for each ineligible 
income quartile (Figure 1). These Kaplan-
Meier survival curves reflect the probabil­
ity of graft survival on each day, adjusted 
for censoring. That is, the probability of 
graft failure on day t is given by the num­
ber of failures on day t divided by the num­
ber of patients who are still in the sample 
on day t. The Kaplan-Meier survival curve 
represents the residual remaining after the 
proportion of failures has been subtracted 
from 100 percent. 
Assuming that the coverage extension 
would have taken effect on January 1, 2000, 
and would have covered those who had 
been transplanted after January 1, 1997, we 
then calculated the expected change in the 
graft survival rates for low income patients 
that would have occurred with lifetime cov­
erage. For example, in 1997 there were 636 
high income ineligibles transplanted and 
1,858 low income ineligibles transplanted. 
Assuming that the coverage increase would 
have caused the survival of the low income 
patients to track the survival for the high 
income patients after January 1, 2000, the 
Kaplan-Meier plots (Figure 2) illustrates 
the survival benefit for patients in income 
quartile 1. 
Figure 2 illustrates the actual graft sur­
vival of low income ineligibles and the 
graft survival that the low income ineli­
gibles would have experienced had the 
coverage extension been applied. In other 
words, the slope of the low income sur­
vival curves becomes equal to the slope of 
the high income survival curve on Janu­
ary 1, 2000. Because following each patient 
individually from their respective dates 
of transplantation to the end of the year 
2002 would be computationally difficult, 
we assume that each patient transplanted 
during a given year was transplanted at the 
5  To obtain these estimates, we regressed accumulated costs as 
a function of the days pre- and post-failure. The slope estimates 
give the daily costs pre and post failure. 
6  The intercepts of the cost curves pre and post failure give the 
extra costs above and beyond the daily costs of treating a patient 
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midpoint of the year, July 1st. Assuming 
transplants occurring within a given year 
are randomly distributed across the 365 
days within that year, this strategy should 
yield a reasonable approximation of the 
results we would have obtained if we were 
able to perform separate calculations for 
each of our patients individually. The num­
ber of extra grafts saved over the 3-year 
period was calculated by applying the pre­
dicted survival probability with coverage 
to the number of low income ineligible 
patients with functioning grafts on January 
1, 2000, and subtracting the number of pre­
dicted surviving grafts without coverage 
each day from January 1, 2000 to Decem­
ber 31, 2002. This calculation is done for 
each day until December 31, 2002, 3 years 
after the coverage increase and 5.5 years
after transplantation. 
We repeat this methodology for individ­
uals transplanted in 1998, 1999, 2000, 2001, 
and 2002. For individuals transplanted 
in 1998, the divergence in predicted and 
actual survival probabilities for low income 
ineligibles occurs at day 730 because Janu­
ary 1, 2000, corresponds to 2 years after 
transplantation for the 1998 cohort. Simi­
larly, the predicted and actual probabilities 
diverge for the 1999 cohort at day 365. For
the 2000, 2001, and 2002 cohorts, the sur­
vival for high and low income cohorts are 
exactly equal because the coverage exten­
sion would have already been in effect 
when these patients were transplanted. 
We assumed that the benefits to the cover­
age extension begin even before the expi­
ration of the 3-year coverage. The reason 
for this assumption is that for patients in
quartile 1, the income related disparity 


























700 Predicted Survival 
Actual Survival 





























in graft survival occurred sometime dur­
ing the second post transplant year. The 
reasons for this are unclear. It is possible 
that the income related disparity in graft 
loss appeared before the expiration of the 
third year of coverage because individu­
als, knowing that their coverage will expire 
anyway, stop taking their medications prior 
to the end of the third post transplant year. 
Alternatively, they may hoard their medica­
tions during this time, taking less than the 
recommended doses to save medication for 
after the third year of coverage expires.7 
accumulation Method 
Using the results found in Woodward et 
al. (2001; 2008) that Medicare’s 3-year cov­
erage extension for all patients and lifetime 
coverage of immunosuppression medica­
tion for elderly and disabled individuals 
eliminated the income related disparity in 
graft survival rates, we assumed that the 
potential benefits of a coverage extension 
to those currently ineligible would have 
accrued to patients in the bottom three Zip 
Code median income quartiles rather than 
individuals in the highest income quartile, 
who are likely to be able to afford the med­
ication even after Medicare’s drug cover­
age expires. We estimated the impact on 
Medicare’s net cash flows by combining 
7  Throughout the study, we use conservative estimates of costs 
and generous estimates of benefits. Therefore, our estimates 
r epresent best case predictions of what would occur with a 
 coverage increase. 
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 the cumulative cash outflows, determined 
by the additional daily expenditures on 
medication, with the cumulative daily cash 
inflows, measured by the cost savings asso­
ciated with avoiding graft failures. These 
daily cumulative inflow and outflow values 
are the summation of daily inflows and out­
flows from January 1, 2000 to December 
31, 2002. 
Assuming a conservatively estimated 
yearly cost of immunosuppression medi­
cations of $8,000 gives an estimated daily 
medication cost of $16.6 (assuming a 
20-percent coinsurance rate). Using our 
estimates of the extra costs associated with 
graft failure, the estimated survival benefit 
to the low income ineligibles, the numbers 
of patients in each income cohort, and the 
daily cost of immunosuppression medica­
tion, we estimated the expected cost differ­
ence to Medicare that would have occurred 
if the lifetime coverage had been extended 
to the ineligible patients in our sample. 
We also considered how sensitive our 
results would be to changes in parameter 
values. Parameter subjected to this sensi­
tivity analysis included: the daily cost dif­
ferential between patients with functioning 
grafts and those on maintenance dialysis, 
the additional cost that occurs on the day 
before graft failure, and the income related 
disparity in kidney graft survival. We calcu­
lated the impact on the cost effectiveness 
ratios if we double each of the aforemen­
tioned parameters one at a time, leaving 
everything else constant. 
reSUltS 
We applied the methodology previously 
discussed to calculate the number of graft 
failures avoided and the impact on Medi­
care’s cash flows from each transplant year 
cohort broken down by income quartile. 
Patients in the lowest income quartile 
experienced the biggest difference in graft 
survival compared to patients in the high­
est income quartile, so this group would 
experience the largest benefit from the 
increased drug coverage. Patients trans­
planted in 2001 experienced no graft sur­
vival benefit in the year 2000, and patients 
transplanted in 2002 experienced no graft 
survival benefit in the years 2000 and 2001 
because these cohorts had not yet been 
transplanted. Similarly, with regard to the 
extra cost of immunosuppression medi­
cations, individuals transplanted in 1998 
would not have incurred any additional 
costs in the year 2000 because the year 
2000 corresponds to this cohort’s third 
post transplant year, for which they were 
already eligible for coverage. Individu­
als transplanted in 1999 would not have 
incurred any additional costs until 2002, 
and individuals transplanted in 2000, 2001, 
and 2002 would not have incurred any addi­
tional costs in 2000, 2001, or 2002 because 
these years are within the existing 3-year 
coverage window. 
To illustrate the method by which accu­
mulated costs and benefits were calculated, 
Figure 3 shows graphically the calculation 
for the cohort of patients transplanted 
in 1998 belonging to the lowest income 
quartile. By the end of 2002, outflows and 
inflows for this cohort are roughly equal. 
Among patients in this income quartile 
transplanted in 1997 outflows are greater 
than inflows in each year, and for patients 
in this income quartile transplanted after 
1998 inflows are greater than outflows. 
Because patients in quartile 1 would have 
experienced the largest improvement in 
graft survival, this is the cohort of patients 
most likely to demonstrate a net cost sav­
ings over the period studied. We repeated 
the same process for the other income 
quartiles and transplant years to obtain our 
accumulated net cash flows. 
Results aggregated by transplant cohort 
and income quartile suggest that in 2000, 























































the increased medication coverage would 
have resulted in 103 grafts saved in 2000, 
138 additional grafts saved in 2001, and 167 
additional grafts saved in 2002 (Table 2). 
Net incremental cash flows to Medicare, 
calculated as incremental inflows minus 
incremental outflows would have totaled 
-$2.40 million in 2000, -$7.82 million in 
2001, and -$12.14 million in 2002 (Table 2). 
These incremental benefit and incremen­
tal cost estimates imply cost effectiveness 
ratios of $23,251 per graft failure avoided in 
2000, $56,712 avoided in 2001, and $72,684 
avoided in 2002. 
Given the large incremental costs to 
Medicare of extending coverage to all 
transplant recipients, we calculated the 
incremental costs associated with extend­
ing coverage only to patients residing in the 
lowest Zip Code median income quartile 
HealtH Care FinanCing review/winter 2008-2009/Volume 30, Number 2 102
(Table 2). These patients would have expe­
rienced the largest benefit of extended 
coverage because the income related dis­
parity for this group is the largest. Extend­
ing coverage to only this group would have 
resulted in a cost savings to Medicare of 
$0.24 million in 2000, 0.78 million in 2001, 
and $1.08 million in 2002. These results 
are consistent with Kasiske et al. (2000), 
who projected a cost savings assuming 
only the lowest income patients receive
lifetime coverage. 
Results of the sensitivity analyses con­
ducted are reported in Table 2. Doubling 
each parameter, one by one, did not pro­
duce a cost savings assuming that individ­
uals of all four income quartiles would be 
eligible for the benefit. The parameters with 
the largest impact were the income related 
disparity in graft survival and the daily cost 
Table 2
 
Cost-Effectiveness Calculations Based on Accumulated Net Cash Flow Estimates
 



















Coverage Extension to All Patients 
2000 $ 6.25 $3.85 -$2.40 103 $ 23,251 
2001 17.84 10.03 -7.82 138 56,712 
2002 28.22 16.08 -2.14 167 72,684 
Coverage Extension Limited to Patients in lowest Income Quartile 
2000 $159 $1.83 $024 51 - $ 4,662
 
2001 4.62 5.41 0.78 65 -12,010
 






Differential x 2 
Additional Pre! 
Post Failure 
Costs x 2 
Income Related 
Disparity x 2 
2000 $23,251 $ 4,074 $ 5,101 $1,187 
2001 56,712 11,591 29,067 8,539 
2002 72,684 3,786 45,294 10,329 
NOTE: Numbers in the bottom panel are cost effectiveness ratios obtained from the sensitivity analysis 
SOURCE: Page, TF _, Florida International University, and Woodward, R.S, University ot New 11ampshire; using the 2005 U.S. Renal Data 
System release 
differential. Even using these implausibly 
high benefit and low-eost parameter values, 
we still obtained a net cost to Medicare. 
Therefore, our main result, that extending 
lifetime coverage to all transplant recipi­
ents would have increased Medicare's 
net costs, did not depend heavily on the 
assumption we made in our analysis. These 
calculations also suggest that for a cover­
age extension to generate cost savings 
after 2003 (data not available), there would 
have to be dramatic changes in either the 
characteristics of transplanted patients or 
the costs of treatment. 
CONCLUSION 
Although we estimated a cost savings 
when the coverage extension was applied 
only to patients in the lowest income 
quartile, these estimates must be inter­
preted with caution. In reality, a proposal 
to extend coverage to only patients in the 
bottom income quartile would likely be 
unpopular and perhaps deemed unfair. 
Covering only the lowest income patients 
would likely result in signilicant crowd­
out, where higher income individuals may 
decrease their labor supply to avoid having 
to pay for the costly medications outcof­
pocket. Lastly, the favorable cost effectivcL 
ness ratios suggested by this exercise 
depended heavily on the assumption that 
the disparity between income quartiles 1 
and 4 that appears during the second post 
transplant year is related to the cancella­
tion of coverage at the beginning of the 
fourth post transplant year. 
'Inroughout our analysis, we calculated 
accumulated inflows and outtlows in 1 
year cohorts and assumed that patients 
were transplanted in the middle of the 
year. 'Inis assumption did not change the 
costs and benefits experienced by each 
transplant-year cohort, but it could have 
affected the distribution of these costs and 
benefits for 2000, 2001, and 2002. We also 
made conservative assumptions about the 
additional cost of the medication, and gen­
erous assumptions about the benefits of 
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extended coverage. Therefore, these large 
negative estimated cashflows should be 
taken to represent best case estimates of 
what would have occurred had Medicare 
extended drug coverage to all transplant 
recipients. Although Yen and colleagues 
(2004) concluded that extending lifetime 
coverage to all transplant patients would 
produce a net societal savings, the current 
study considered whether extending life­
time coverage to all transplant recipients 
would result in immediate cost savings 
only to Medicare. Showing an immediate 
cost savings to Medicare would present a 
stronger argument for implementing such 
a coverage extension, even in periods of 
Federal budgetary shortfalls. 
We found evidence to suggest that 
extending Medicare’s lifetime coverage of 
immunosuppression medications to all of 
the non-elderly, non-disabled population 
of kidney transplant recipients would have 
resulted in a significant additional cost to 
Medicare. Although there would have 
been savings associated with avoiding graft 
failure through increased drug coverage, 
these incremental benefits would have been 
heavily outweighed by the incremental 
costs of covering all transplant recipients, 
most of whom would have experienced no 
improvement in graft survival outcomes. 
Extending the coverage only to individu­
als residing in the lowest Zip Code median 
income quartile most likely to benefit from 
extended coverage would have produced 
cost savings to Medicare, although this 
result would have depended heavily on the 
generous assumptions regarding the medi­
cal benefit to these individuals. 
In this article, we considered only the 
point of view of Medicare’s costs, the larg­
est payer after transplantation. Although 
this point of view is a natural starting point, 
future investigations are needed to exam­
ine the societal and patient perspectives, 
which would incorporate improved  quality 
of life and labor market productivity 
increases into the benefit measures. Add­
ing these additional benefits of improved 
outcomes to the analysis could suggest a 
net societal benefit to extending lifetime 
coverage to all transplant recipients. 
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